SCHEMBL4707445

SCHEMBL4707445

CCn1nc(-c2cccc(F)c2)c(C(C)=O)c(Nc2ccc(CO)cc2)c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.62
HTR1A P08908 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
BRD4 O60885 2/20 0.37
CREBBP Q92793 2/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
FYN P06241 1/20 0.36
IL2 P60568 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
FPR1 P21462 1/20 0.35
FPR2 P25090 1/20 0.35
ALPL P05186 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707025 0.92 PDE4B (0.52) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4708777 0.89 PDE4B (0.62) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4709069 0.89 PDE4B (0.62) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4708743 0.88 PDE4B (0.49) PDE4BBRD4CREBBPPDE4APDE4D
SCHEMBL4707663 0.88 PDE4B (0.64) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4708476 0.88 PDE4B (0.79) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707884 0.86 PDE4B (0.45) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4050693 0.85 PDE4B (0.43) PDE4BADORA2AADORA2BADORA1FYN
SCHEMBL4706986 0.85 PDE4B (0.57) PDE4BSMN1; SMN2PDE4APDE4CPDE4D
SCHEMBL4706532 0.85 PDE4B (0.57) PDE4BHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885HTR1A 1051/4885ADRA1D 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.